An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system

Nature Medicine

Volumn 6, Issue 7, 2000, Pages 808-811

  Brinkmeier, Heinrich ^a   Aulkemeyer, Peter ^a   Wollinsky, Kurt H ^b   Rüdel, Reinhardt ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Rehabilitationskrankenhaus Ulm gGmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; PENTAPEPTIDE; RECEPTOR SUBUNIT; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; DISEASE ACTIVITY; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; NERVE BLOCK; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

CEREBROSPINAL FLUID; GUILLAIN-BARRE SYNDROME; HUMANS; MULTIPLE SCLEROSIS; NEURONS; OLIGOPEPTIDES; SEQUENCE ANALYSIS, PROTEIN; SODIUM CHANNEL BLOCKERS; TUMOR CELLS, CULTURED;

EID: 0033943798     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/77543     Document Type: Article

References (18)

1. Gutmann, L. & Gutmann, L. Axonal channelopathies: an evolving concept in the pathogenesis of peripheral nerve disorders. Neurology 47, 18-21 (1996).
2. Waxman, S.G. Sodium channel blockade by antibodies: a new mechanism of neurological disease? Ann. Neurol. 37, 421-423 (1995).
3. + currents in isolated rat myelinated nerve fibers. Ann. Neurol. 37, 436-442 (1995).
4. + current. Brain 119, 457-463 (1996).
5. Brinkmeier, H. et al. Factors in the cerebrospinal fluid of multiple sclerosis patients interfering with voltage-dependent sodium channels. Neurosci. Lett. 156, 172-175 (1993).
6. + channel blocking factor in the cerebrospinal fluid. Pflügers Arch. 421, 552-557 (1992).
7. Aulkemeyer, P., Brinkmeier, H., Wollinsky, K.H. & Rüdel, R. The human endogenous local anesthetic-like factor (ELLF) is functionally neutralized by serum albumin. Neurosci. Lett. 216, 37-40 (1996).
8. Brinkmeier, H., Seewald, M.J., Wollinsky, K.H. & Rüdel, R. On the nature of endogenous antiexcitatory factors in the cerebrospinal fluid of patients with demyelinating neurological disease. Muscle Nerve 19, 54-62 (1996).
9. Griffin, J.W. et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann. Neurol. 39, 17-28 (1996).
10. Parry, G.J. n Guillain-Barré Syndrome 1-200 (Thieme Medical, New York, 1993).
11. Köller, H., Siebler, M. & Hartung, H.P. Immunologically induced electrophysiological dysfunction: implications for inflammatory diseases of the CNS and PNS. Prog. Neurobiol. 52, 1-26 (1997).
12. Sakurai, M., Mannen, T., Kanazawa, I. & Tanabe, H. Lidocaine unmasks silent demyelinative lesions in multiple sclerosis. Neurology 42, 2088-2093 (1992).
13. Würz, A. et al. Cerebrospinal fluid and serum from patients with inflammatory polyradiculoneuropathy have opposite effects on sodium channels. Muscle Nerve 18, 772-781 (1995).
14. Aulkemeyer, P. et al. The small sodium-channel blocking factor in the cerebrospinal fluid of multiple sclerosis patients is probably an oligopeptide. J. Neurol. Sci. 172, 49-54 (2000).
15. Weber, F., Brinkmeier, H., Aulkemeyer, P., Wollinsky, K.H. & Rüdel, R. A small sodium channel blocking factor in the cerebrospinal fluid is preferentially found in Guillain-Barré syndrome: a combined cell physiological and HPLC study. J. Neurol. 246, 955-960 (1999).
16. Catterall, W.A. Cellular and molecular biology of voltage-gated sodium channels. Physiol. Rev. 72, S15-S48 (1992).
17. + channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol. Pharmacol. 40, 756-765 (1991).
18. Hamprecht, B., Glaser, T., Reiser, G., Bayer, E. & Propst, F. Culture and characteristics of hormone-responsive neuroblastoma X glioma hybrid cells. Methods Enzymol. 109, 316-341 (1985).